Scientific article
Open access

News in angiology and hemostasis

Published inRevue médicale suisse, vol. 12, no. 500, p. 13-16
Publication date2016

This update describes contemporary studies of clinical relevance in angiology and hemostasis. We discuss newer developments for the treatment of haemophilia, with a focus on drugs with longer-half lives. Direct anticoagulants (DOAC: rivaroxaban, apixaban, edoxaban and dabigatran) and their approved prescription in Switzerland are summarized, with a description of antidotes that will be available in the near future. We will present new data on the utility of cancer screening at the diagnosis of idiopathic venous thromboembolism (VTE) and on the evaluation of DOAC in patients with cancer-related VTE. Finally, new studies evaluating the clinical risk-benefit of anticoagulation bridging for patients with vitamin K antagonists undergoing procedures do not support the use of such bridging in the majority of patients.

  • Anticoagulants/pharmacology/therapeutic use
  • Drug Approval
  • Hemophilia A/therapy
  • Hemostasis/drug effects
  • Humans
  • Switzerland
  • Vitamin K/antagonists & inhibitors
Citation (ISO format)
BOEHLEN, Françoise, BLONDON, Marc, FONTANA, Pierre. News in angiology and hemostasis. In: Revue médicale suisse, 2016, vol. 12, n° 500, p. 13–16.
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation04/06/2016 11:23:00 AM
First validation04/06/2016 11:23:00 AM
Update time03/15/2023 12:15:49 AM
Status update03/15/2023 12:15:49 AM
Last indexation01/16/2024 8:34:34 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack